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Abstract
T cells orchestrate the adaptive immune response, making them targets for immunotherapy. Although immunosuppressive
therapies prevent disease progression, they also leave patients susceptible to opportunistic infections. To identify novel
drug targets, we established a logical model describing T-cell receptor (TCR) signaling. However, to have a model that is
able to predict new therapeutic approaches, the current drug targets must be included. Therefore, as a next step we
generated the interleukin-2 receptor (IL-2R) signaling network and developed a tool to merge logical models. For IL-2R
signaling, we show that STAT activation is independent of both Src- and PI3-kinases, while ERK activation depends upon
both kinases and additionally requires novel PKCs. In addition, our merged model correctly predicted TCR-induced STAT
activation. The combined network also allows information transfer from one receptor to add detail to another, thereby
predicting that LAT mediates JNK activation in IL-2R signaling. In summary, the merged model not only enables us to
unravel potential cross-talk, but it also suggests new experimental designs and provides a critical step towards designing
strategies to reprogram T cells.
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Introduction
A number of receptor signaling networks have been elucidated
beginning with the proximal events at the receptor, initiated by
ligand binding, and extending down to the level of transcription
factor activation. However, this top-down approach to describe
pathways usually ignores the potential input coming from other
receptor systems. In vivo, cells are rarely exposed to only one signal
at a time and therefore require the capacity to integrate multiple
signals coming from many receptors simultaneously. Thus, a one-
to-one relationship between receptor triggering and a functional
outcome is usually not possible, as the result of receptor
stimulation depends upon the temporal sequence of inputs from
multiple receptors. Hence, in order to investigate the cross-talk
between receptors, without testing all possible combinations of
stimuli, strategies are required to efficiently derive the global
signaling network taking advantage of the known isolated top-
down pathways of receptors.
A system for which a number of receptors have been
characterized and that provides both easy access to material and
a short path to medically relevant applications are T cells. T
lymphocytes are a central component of the immune system and
orchestrate many aspects of the adaptive immune response. This
function makes T cells an attractive target for therapeutic
intervention, e.g. for treating autoimmune diseases, suppressing
immune responses directed against organ transplants, and even in
stimulating immune responses against cancer [1]. However, the
current immunosuppressive strategies affect all T cells and not
only disease-relevant subsets and thus increase the susceptibility to
opportunistic infections. In order to circumvent this problem and
to identify new targets for potential therapeutic intervention, the
interrelationship of the existing signaling machineries must first be
understood.
We initially focused our attention on the T-cell receptor for
antigen (TCR), which recognizes peptides bound to HLA-
molecules. The TCR ultimately determines whether a T cell will
become activated or not [2,3]. However, in order to be able to
compare a newly developed strategy with existing therapies, the
current drug targets (i.e. receptors or signaling molecules) must
first be included in the network. The interleukin-2 receptor (IL-
2R) is one such therapeutic target. Activation of T cells via the
TCR is known to enhance both the secretion of the autocrine
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high affinity form of the IL-2R. On one-hand IL-2 is used to
enhance anti-tumor responses or its receptor inhibited in the case
of immune suppression [4].
The investigation of cross-talk immediately presents the
problem of how to merge signaling networks. Therefore, in order
to compare intervention in the TCR signaling pathway with the
present therapeutic strategies, we created a tool to generate a
merged model that combines our previous logical TCR-signaling
network with the IL-2R network.
The IL-2R exists in three forms. The low affinity variant
consists of the IL-2Ra-chain (CD25) alone. The intermediate
affinity receptor is composed of the IL-2Rb-chain and the
common c-chain, which is shared with other cytokine receptors.
The high affinity form of the IL-2R contains all three chains
together and mediates the autocrine feedback-loop [5]. The a- and
b-chain mediate ligand binding to initiate signaling via activation
of the receptor-associated Janus-kinase 3 (JAK3). Active JAK3
phosphorylates the b-chain of the IL-2R resulting in the
recruitment of JAK1 and the adaptor Shc. JAK1 and JAK3 both
phosphorylate STAT molecules. Phosphorylated STAT proteins
dimerize and translocate to the nucleus. In parallel, Shc recruits
Grb2/SoS leading to activation of the RAS-RAF-MEK-ERK
cascade. PI3K, JNK, and p38 are also reported to be activated by
the IL-2R [5]; however the mechanisms of their activation are not
well described.
A number of the key molecules in TCR signaling are also
utilized by the IL-2R [5]. The interaction of different pathway
modules like ERK and PI3K has been well studied for TCR
stimulation. However, the cross-talk with other receptor systems
like the IL-2R has rarely been addressed, if at all. It is therefore a
priori not clear how the common signaling elements of these two
pathways interact: can they be cross-activated to enhance
signaling, are they used competitively leading to an effective
inhibition, or do these modules function independently of one
another. Here, our method to merge logical models of signaling
networks allows us to identify potential points of receptor cross-talk
in a semi-automated manner. To approach a validated version of
the signaling network, the merged logical model enables us to
design experiments to determine whether potential cross-talks exist
or not. Following validation of the IL-2R network in human T-cell
blasts, the merged model predicted that STAT signaling should
also be initiated upon TCR triggering, which we then verified
experimentally. Moreover, our model predicted that LAT should
be activated following IL-2 stimulation, which we could verify as
well. The ability to reveal new signaling elements in both TCR
and IL-2R signaling opens the possibility of gaining new insights
into the mechanisms of signaling in T cells that may ultimately
identify new targets for T cell-specific therapy.
Methods
Ethics statement
Approval for these studies was obtained in writing from the
Ethics Committee of the Medical Faculty at the Otto-von-
Guericke University, Magdeburg, Germany. Informed consent
was obtained in writing in accordance with the Declaration of
Helsinki.
Logical modeling of signaling networks
The simplest model of signaling processes is to collect data on
direct molecular interactions in the form of logical formulas, that
can be written down in propositional logic [3]: We introduce a
logical variable for each signaling component and write down
implication formulas for experimentally proven knowledge
statements like ‘‘MEK activates ERK’’ as MEKRERK and ‘‘STAT3
or STAT5 can induce Blimp-1 expression’’ as STAT3 OR STAT5R
Blimp-1. The precise meaning of the ON-state for the logical
variable representing a signaling component depends on the
biological context. It can refer to an increase in the amount of a
substance (e.g. IP3, DAG), its phosphorylation (e.g. LAT), or its
recruitment to the membrane or association with other proteins
(e.g. Grb2/SoS, PI3K) (the specific meaning for the individual
components can be found in Table S1). This interaction network
describes the dependencies of activation/inactivation, but does not
model the dynamics of these events. The lack of temporal
information for the majority of the network components prevents
the evaluation of the network using synchronous or asynchronous
updates. The propagation of signals would correlate with the
number of intermediate steps rather than actual chemical reaction
rates. Yet the transient nature of some signals requires at least two
networks to properly incorporate all interactions. In particular the
discretized versions of negative feedbacks require the ability to
represent two mutually exclusive states. As done previously for the
TCR network [3], we introduce two time scales for the model:
Every implication is assigned a time horizon indicating its validity.
Those implications that are only valid for the first time period are
called early implication formulas, while those valid during the second
period are called late implication formulas. Implications valid for both
time periods are designated permanent implication formulas.A
permanent implication formula in the TCR network is for
example RASRRAF, whereas CCBLR AND ZAP70RCCBLP1
exemplifies a late implication, thus the dynamics of activation are
considered implicitly.
The aim of logical modeling is not to describe the dynamics of a
signaling network, but to maintain the interactions rather than
when or how. The time horizon allows us to segregate events into
discrete steps, which is particularly important in the case of
feedbacks. It is clear that the activation of the feedback requires
the activity of its preceding signaling elements. The quasi-
continuous activity of the signaling components is mapped to
discrete states and the ON-state corresponds to full activity.
Therefore, there exists a time delay between the detection of the
Author Summary
The cells of the mammalian immune system do not exist in
isolation, but rather form an integrated network that is
constantly scanning the body for signs of ‘foreign’
invasion. Working together, these cells possess the ability
to repel invaders and thereby establish protective immu-
nity. One central population in this network are T
lymphocytes; whose role it is to coordinate the activity
of the adaptive arm of defense. However, T cells constantly
receive multiple inputs and therefore it is not clear how
they are able to reach a decision. Traditionally, these
inputs are studied in isolation using a top-down or
stimulus-response approach. Confounding this issue is
that our knowledge of these input pathways is not cell-
type-specific, but rather represents the sum of all
knowledge related to a given stimulus. Therefore, we
have undertaken to validate signaling pathways in primary
human T cells. We are particularly interested to study the
cross-talk between pathways to see how common
elements are utilized to make specific decisions that
determine cell fate. In doing so, we have identified new
components in what were considered to be well-charac-
terized receptor pathways.
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early and late time horizon. Considering transient signaling events
the early horizon corresponds to the ascending flank of the signal
when the activators dominate and the late horizon to the
dominance of negative regulators along the descending flank of
the signal. However, since the states of all components are
discretized, the state of the logical model is naturally mapped to
the peak of the signal (early times) and the adaptation/shutoff of
the signaling cascade (late time points).
We assume that in signaling networks a component cannot
change its state from active to inactive or vice versa without the
influence of either a change of state for other components or
external stimulation. For some proteins inactivation may occur via
intrinsic mechanisms, e.g. the intrinsic GTPase activity of RAS
may result in its inactivation. However, as this activity is far slower
than the catalyzed inactivation by GTPase-activating proteins
(GAPs), for the purpose of simplification, it is excluded from the
model. As introduced previously [6], to model that a component
that is not an input to the network (i.e. it has at least one
predecessor) can only change its state of activation if there is a
reason for it, we introduce the inverse direction of dependency.
Therefore we collect all statements with the same right-hand-side
leading to activation in one statement A1 OR … OR An R B that is
transformed to the if-and-only-if (IFF) clause A1 OR … OR An « B.
This implies that B can only be active if at least one of the A1,… ,
An is active. We can formalize the standard signaling network in
terms of IFF-clauses: Let the IFF-clauses of a given time horizon
be denoted as Si with i[1...s. We can then identify the formula
S~ANDs
i~1Si with the network of the biological unit considered:
All logical statements Si with the same time horizon should be valid
at the same time to model the global behavior of the unit.
Checking these amounts to solving a satisfiability (SAT) problem
for the formula S, and each feasible solution represents one
possible state of the signaling network. The fact that seemingly
simple formulas with AND, OR, and NOT operations are used to
represent the information is not a sign of low complexity: In fact,
IFFSAT networks are able to encode the NP-complete 3-SAT
problem [6], and it is well known that any logical formula can be
written in 3-SAT form. In particular, the networks in this paper do
not have any of the structures that make solving SAT with some
specialized method easier. For more details about the formalism of
propositional logic we refer to [7]. With this model at hand, we
can then answer relevant biological questions such as predicting
the cellular response to a given stimulation using standard solver
techniques from computational logic.
An important feature of the logical model is the possibility to
detect infeasible subsystems. A typical situation is that following an
experiment a subset K of components An is known to be ON or
OFF. If this fixation pattern K of components is a possible solution
of the network, i.e. every clause Si can be satisfied, then the fixation
pattern is feasible otherwise the fixation pattern An is called
infeasible. An infeasible pattern, i.e. a conflict within the
experimental data, can be due to a modeling error or result from
a negative feedback loop that prevents signaling and should only
be active at a later time point. The logical network allows us to
compute a set of minimal interventions that permits a feasible
solution for the fixation pattern K. These minimal interventions
may represent a solution to the modeling errors, point out
inconsistent data in the literature [3], or identify interactions
involving negative feedback loops. In the latter case, the
interactions are late implication formulas [3]. We note that, as
described in [6], negative feedback loops must not necessarily lead
to infeasibility of the network and thus, in general, need not be
removed, but can be ‘‘compensated’’ by another component. As
an example consider the negative feedback loop PAG « CSK, NOT
CSK « LCKP1, LCKP1 « FYN, FYN AND NOT TCRB « PAG
(Figure S1) occurring in the TCR network. It does not
immediately yield an infeasible logical model since TCRB=1,
PAG=0, CSK=0, LCKP1=1, FYN=1, is one feasible assign-
ment to the variables. In this case the negative feedback loop is
compensated by the additional input TCRB to the IFF-clause
producing PAG (Figure S1). Nevertheless, detecting reasons for
infeasibility is of major interest, e.g. for monitoring a modeling
process or unraveling possible temporal information about
interactions. The method described in [6] allows us to efficiently
identify all causes of infeasibility and thereby reveals feedback
loops as a side result.
Cell culture and stimulation
Peripheral human T cells were isolated from heparinized blood
collected from healthy volunteers using Biocoll (Biochrom AG,
Germany) and a Pan T-cell isolation kit II (Miltenyi Biotec,
Germany). After resting overnight, T cells were stimulated with
plate-immobilized anti-CD3 (OKT3 murine hybridoma, Institute
of Molecular and Clinical Immunology, Otto-von-Guericke
University, Germany) and anti-CD28 (murine hybridoma
248.23.2, Institute of Molecular and Clinical Immunology, Otto-
von-Guericke University, Germany) in culture medium (RPMI-
1640 supplemented with 10% heat-inactivated FBS, and 2 mg/ml
ciprofloxacin) for 48 hr. After washing twice with RPMI 1640,
cells were rested in fresh culture medium for 24 hr.
Flow cytometry
To determine the number of CD25
+ cells 1610
6 T lymphocytes
were washed twice with PBS and incubated with FITC anti-CD25
(BD Biosciences) for 15 min. at 4uC, followed by two additional
washing steps. The number of apoptotic cells was determined
using an Annexin V/FITC Kit (Bender MedSystems) according to
the manufacturer’s instruction. Cells were immediately analyzed
by flow cytometry (FACS caliber, BD Biosciences).
Restimulation and inhibition
To identify proteins that became activated upon IL-2R
signaling, rested T-cell blasts were stimulated with 100 U/ml IL-
2 (Tebu-Bio GmbH, Germany) for the indicated time. To clarify
the role of different kinases, T-cell blasts were pre-incubated for
30 min. with either 10 mM PP2, 1 mM wortmannin, 1 mM
Go ¨6976, 1 mMG o ¨6983 or 1 mM Jak Inhibitor I (Calbiochem,
Merck Chemicals, Germany), followed by the addition of IL-2 for
the indicated time. Reactions were stopped by addition of ice-cold
PBS (Biochrom AG, Germany).
Immunoblotting
Cells were lysed (1% N-dodecyl b-D-maltoside, 1% NP-40,
1 mM vanadate, 1 mM PMSF, 50 mM Tris pH 7.5, 10 mM NaF,
10 mM EDTA pH 7.5, 165 mM NaCl) for 20 min on ice and
centrifuged at 13000 rpm, 10 min, 4uC. The post-nuclear extracts
were separated on 10% SDS-PAGE under reducing conditions.
Proteins were transferred onto nitrocellulose membranes (Hybond,
Amersham Pharmacia Biotech) and immunoblotting was per-
formed using anti-pS473-AKT (93H12), anti-pT202-pY204-
ERK1/2, anti-pT180-pY182-p38 MAPK, anti-pT183-pY185-
JNK, anti-pY171-LAT, anti-pY705-STAT3 (D3A7), anti-pY694-
STAT5 (C11C5); (all Cell Signaling Technology), anti-phospho-
tyrosine (4G10, murine hybridoma, Institute of Molecular and
Clinical Immunology, Otto-von-Guericke University, Germany)
and b-actin (Sigma, Germany), followed by incubation with the
TCR and IL-2R Cross-Talk
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anti-rabbit. Visualization was performed using enhanced chemi-
luminescence (ECL, Amersham Pharmacia Biotech) according to
the manufacturer’s instructions. Films were scanned with an Epson
Perfection 4990 Photo scanner (Epson America, Torrance, CA).
Results/Discussion
Validating the IL-2R signaling network in human T-cell
blasts
A number of studies have analyzed the effect of IL-2 on T-cell
proliferation, survival, differentiation, and population dynamics
[8–10]. Our study differs from these as our focus is on the
components of IL-2 signaling and their interactions, rather than
on the cellular response to IL-2. Starting with the Nature pathway
for the IL-2R [11], we generated our own IL-2R signaling network
(Figure 1), which contains 68 components and 69 clauses. As done
previously for the TCR model [3], only interactions that are
reported for IL-2R signaling by at least two independent sources
have been included. We favored results generated with untrans-
formed cells, although, due to the limited number of studies and in
contrast to the stringency applied to the TCR model, we also
considered results that had been generated in T-cell lines.
The IL-2R network was then validated experimentally using
human T-cell blasts. The cells were viable and expressed the high
affinity receptor for IL-2 (Figure S2). First, we tested whether all
key molecules are indeed activated by the IL-2R upon ligand
binding (Figure 2A) thereby targeting the major pathways in the
network. Our experiments confirmed the activation of the main
downstream targets of the IL-2R: STAT3 and STAT5, the
activation of the MAP kinases ERK and JNK, as well as the
activation of the PI3K pathway by visualizing phosphorylation of
its downstream target AKT. We also found that the pathways of
IL-2R signaling show different sensitivities to the dose of IL-2
used. In particular STAT activation is detectable at lower doses
than MAPK activation (Figure S3), suggesting different kinase
dependencies that may explain the different sensitivities of MAPK
and STAT activation. The activation of p38 was not consistently
observed over a series of 6 experiments in total (Figure 2B).
Furthermore, using Jak Inhibitor I we could demonstrate that all
of the target molecules investigated depend on the activation of
Janus kinases confirming that JAK3 and JAK1 are the critical
kinases immediately downstream of the IL-2R (Figure 2B). The
only exception is AKT that still shows some inducible phosphor-
ylation in the presence of Jak Inhibitor I. This implies that at least
this pathway depends on a kinase of another family (Figure 2C).
However, the strong reduction after inhibition of the JAK kinases
demonstrates that the PI3K pathway is largely dependent on
JAK1 and/or JAK3, which has not been reported previously.
One report suggests that PI3K is downstream of a Src family
kinase (SFK) in IL-2R signaling [12] (Figure 3A). However, this
was the only report that implicates SFKs, although PI3K activity
following IL-2 stimulation has been reported multiple times (Table
S2). Therefore, to determine whether the data is true for IL-2
stimulation of T cells, we stimulated human T-cell blasts with IL-2
in the presence or absence of the SFK inhibitor PP2 (Figure 3B).
We found that AKT phosphorylation is strongly reduced by PP2
treatment. As a positive control, we tested that STAT activation
remains normal, since SFK activity is not mandatory. In addition,
this experiment suggests that a potential contribution of SFKs to
STAT phosphorylation is irrelevant, as the treatment with PP2
had no influence on either STAT3 or STAT5 phosphorylation
(Figure 3B) [13]. Therefore the connections between SFKs and
STATs were removed. In contrast, the activation of ERK and
JNK is dependent on SFKs (Figure 3B) and to our knowledge this
has not been shown for IL-2R signaling although the induction of
c-fos and c-jun has been reported to be dependent on Lck [14].
Taken together, the Jak Inhibitor I and PP2 experiments suggest
that SFK activity is largely downstream of JAKs (Table S2) since
both inhibitors block AKT, but STAT activation is SFK-
independent. However, Jak Inhibitor I cannot completely block
IL-2-induced AKT activation (Figure 2B). Indeed, one report
demonstrated that IL-2R-mediated Lck activity is partially
independent of JAK3 [13] and therefore is likely responsible for
the weak JAK-independent AKT phosphorylation seen in
Figure 2B.
We next investigated whether PI3K had any influence on other
parts of the IL-2R signaling network by applying the PI3K
inhibitor wortmannin (WM) (Figure 4A). Figure 4B shows that
PI3K does not influence STAT phosphorylation, which is in
agreement with our previous result showing that PP2 treatment
blocked PI3K activity, but did not influence STAT activation. In
contrast, both JNK and ERK are downstream of PI3K (Figure 4B),
which fits nicely with the SFK-dependency of these two MAP
kinases following IL-2 stimulation (Figure 3B). This result also
supports a previous study demonstrating the requirement of PI3K
for ERK activation [15]. We noticed that WM and Jak Inhibitor I,
but not PP2, are able to completely block ERK activation
(Figure 2B, Figure 3B, Figure 4B). Our interpretation of the data is
that ERK requires both Janus kinases and PI3K for activation in a
non-redundant manner. The discrepancies between PP2 and WM
are most likely due to the reversible nature of PP2, such that it is
unable to fully inhibit SFKs, resulting in a residual PI3K-activity
that appears to be sufficient to support weak ERK activation
(Figure 3B). In agreement with this hypothesis, we observe residual
AKT phosphorylation after PP2, but not after WM treatment, as
WM is an irreversible inhibitor (Figure S4).
Numerous studies performed two decades ago had demonstrat-
ed PKC activation upon IL-2R stimulation [16–25]. Virtually all
of these studies demonstrated an increased membrane-associated
PKC activity after IL-2 stimulation using different mouse or
human systems. However, there were also conflicting results as to
the role of PKCs in IL-2R signaling. While some studies, using
PKC inhibitors or phorbol ester-mediated downregulation of
PKCs, found that IL-2-induced T-cell proliferation is PKC-
dependent [16–20] other studies frequently failed to show any
effect [21–23]. In order to clarify this situation and to determine
whether IL-2-induced PKC activation influences the known
signaling events in human T-cell blasts, we treated the cells with
the PKC inhibitors Go ¨6976 and Go ¨6983 (Figure 4B). Go ¨6976 is
an inhibitor of classical PKC isoforms, which depend on calcium,
while Go ¨6983 blocks novel, calcium-independent PKC isoforms.
Therefore we expected that Go ¨6976 would not influence IL-2R
signaling, as it is known that calcium is not triggered following IL-
2R stimulation [23,25]. However, to our surprise Go ¨6976
completely blocked IL-2R signaling. A recent publication
identified Go ¨6976 as an inhibitor of JAK2 of IL-3 signaling in a
tumor cell line and, in an additional control, demonstrated that
Go ¨6976 also blocks IL-2R signaling by inhibition of JAK3 [26].
With this in mind, the results of Go ¨6976 inhibition agree mostly
with the results from Jak Inhibitor I by blocking all readouts in our
system (Figure 2). Also AKT is now completely blocked unlike in
the case of Jak Inhibitor I, which may indicate a reduced
specificity of Go ¨6976 compared to Jak Inhibitor I. Go ¨6983 was
more specific and almost completely blocked ERK activation
suggesting that novel PKCs play a role in ERK activation after IL-
2 stimulation of human T-cell blasts corresponding to a similar
dependency of ERK that was shown for TCR stimulation [27,28].
TCR and IL-2R Cross-Talk
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PI3K, and novel PKCs [3,27,28] suggesting a largely common
ERK pathway in T cells for both the TCR and IL-2R. It remains
an open question where exactly the cross-talk of PKC and PI3K
with ERK takes place and whether the pools involved are
common between TCR and IL-2R signaling. In other cell systems
Figure 1. A graphical representation of the logical network of IL-2R signaling. The top layer represents input nodes: the ligand and the
receptor subunits. Signaling molecules that are either not regulated by IL-2 signaling, i.e. they can be inputs from other receptors, or for which the
corresponding regulation is not known are marked in grey. The bottom layer represents the output, i.e. molecules including transcription factors that
become activated upon IL-2R signaling. Solid black arrows indicate activating interactions with a black circle denoting AND-connections. For clarity,
activating influences with arrows pointing from the bottom to the top are drawn with dashed black lines. Dotted lines mark inhibitory influences that
are expressed as NOT-conditions in the logical network. Detailed descriptions for the interpretation of each node can be found in Table S1.
doi:10.1371/journal.pcbi.1002121.g001
TCR and IL-2R Cross-Talk
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demonstrated [29,30]. PKCs may also influence ERK activation
at the level of RAF by inhibiting the RAF kinase inhibitor protein
(RKIP) or by directly phosphorylating RAF itself [31–33]. The
commonly used signaling components SFKs, PKCs, PI3K, and
RAF/MEK/ERK may play a co-stimulatory role in the cross-talk
of TCR and IL-2R signaling.
In summary, we present a validated IL-2R signaling network
(see Figure 5) containing 68 components and 73 clauses, which was
then used for the merging process. The changes to the network are
summarized in Table S3.
Model merging
Cross-talk between two receptors is mediated by molecules that
are common to both pathways, but for which the upstream
regulation is differentially organized. Thus, in each pathway the
regulation of these common molecules is incompletely described
from the perspective of a merged network that aims at describing
both systems simultaneously. In our example of TCR and IL-2R
signaling, synchronous stimulation of both receptors is likely to
happen during clonal expansion. Here antigenic stimulation of T
cells is still ongoing 30 hours after initial stimulation [34] when the
high affinity variant of the IL-2R has been upregulated [35].
Cross-talk may also come into play earlier, as the production of
autocrine IL-2 begins as early as 2 hours after stimulation [36].
However the simple ‘‘addition’’ of the regulatory events coming
from both receptors may not properly describe their activation in
the merged network.
The prerequisites for merging are that the components of the
systems are standardized, i.e. components with identical names
refer to identical molecules, and the interpretation of their activity
states is consistent (see Figure 6). Then the following types of
questions appear:
1. Implication formulas for the activation of one node have
overlapping, but non-identical left-hand-sides, e.g.
GAB2RSHP2 versus NOT ERK AND GAB2RSHP2. These
clauses differ with respect to ERK. The question is whether
ERK always inhibits SHP2 or whether this is a network-specific
event involving (unknown) additional regulators that ensure
receptor-specificity (see Figure 6A).
2. Two implication formulas for the activation of a node have no
overlap. In the simplest case, the mediators are receptor-
specific and there is no conflict. If downstream components are
activated by one receptor does this mean that these same
components are also activated by the other (see Figure 6B)?
3. Two implication formulas for the activation of a node have no
overlap. It is possible that one is only a simplification of the
other that omits intermediate steps. In the IL-2R network JNK
is activated directly by SFKs. While the TCR network contains
multiple pathways leading to JNK. The first statement is not
wrong, since all of these pathways are themselves SFK-
dependent. However, the information available is not precise
enough to distinguish which pathway is involved (see
Figure 6C).
4. The implications formulas depend on different isoforms, e.g.
novel PKCs (nPKCs) versus PKCe ` which is one member of the
nPKCs. Hence, whenever one isoform (PKCe `) is activated,
every interaction involving the more general class of proteins
(nPKCs) may also be affected and vice versa (see Figure 6D).
This list contains specific examples, however a general problem
occurs when the ‘‘local interaction’’ information taken into
account while constructing signaling networks is of a different
resolution with respect to the proteins involved. The different
forms of inherently incomplete information result in obstacles for
Figure 2. Confirmation of key events of IL-2R signaling in human T-cell blasts. (A) A simplified scheme showing the six major downstream
targets identified for IL-2R signaling are grouped into three classes: The PI3K-pathway (AKT), MAP kinases (ERK, JNK, p38), and STAT signaling (STAT3,
STAT5). Reliable interactions are indicated with solid lines, potential interactions are presented with dotted lines. The kinases responsible for PI3K
activation is not clearly identified and therefore contains the direct information IL-2 activates PI3K (curved line). (B) T-cell blasts were stimulated with
IL-2 for the indicated times. Phosphorlyation of AKT, STAT3, STAT5, p38, ERK, and JNK were analyzed by Western blotting. b-actin was analyzed as
loading control. (C) Revised model taking into account the strong dependence of PI3K/AKT on JAK1/3 (thick arrow).
doi:10.1371/journal.pcbi.1002121.g002
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PLoS Computational Biology | www.ploscompbiol.org 6 August 2011 | Volume 7 | Issue 8 | e1002121Figure 3. PI3K activation, but not STAT activation is strictly Src family kinase-dependent. (A) Our IL-2R signaling network indicates that
only Src family kinases mediate PI3K activation. While STAT activation may be influenced by the Src family kinases Lck and Fyn, Janus kinases alone
are sufficient for STAT activation. The model does not contain any information about the kinases-dependence of JNK and p38 activation such that the
role of Src family kinases remains unclear (dotted lines). (B) T-cell blasts were stimulated with IL-2 for the indicated times in the presence or absence
of the Src family kinases inhibitor PP2. Phosphorlyation of AKT, STAT3, STAT5, p38, JNK, and ERK were analyzed by Western blotting. Note, that the
experiment was performed on one gel and irrelevant lanes have been cut out. b-actin was analyzed as loading control. (C) Revised model removing
the potential link between SFKs and STATs. PI3K is downstream of SFKs and the dependence of PI3K on JAK1/3 is reconnected to an indirect influence
via the effect of JAKs and SFK activation (thick arrows). In addition ERK and JNK are dependent on JAK and SFK while p38 remains independent of
SFKs.
doi:10.1371/journal.pcbi.1002121.g003
Figure 4. Effects of PI3K and PKC inhibitors on IL-2R signaling. (A) The model predicts that inhibition of PI3K activity should not have any
effect STAT or ERK phosphorylation. There exists evidence that PI3K may have an effect on ERK. However, an influence on JNK or p38 is not clear.
Although PKCs are activated upon IL-2 stimulation their influence on any other signaling component has not been demonstrated. (B) T-cell blasts
were stimulated with IL-2 for the indicated times in the presence or absence of the PI3K inhibitor wortmannin (WM) or the PKC inhibitors Go ¨6976 and
Go ¨6983. AKT, STAT3, STAT5, p38, JNK, and ERK were analyzed by Western blotting. b-actin was analyzed as loading control. (C) Revised model
separating the dependencies of ERK and JNK. ERK depends on JAK1/3, PI3K and nPKCs while JNK is only dependent on JAK1/3 and PI3K (thick
arrows).
doi:10.1371/journal.pcbi.1002121.g004
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considering the inverse problem: How can one extract the
signaling network or an arbitrary subnetwork of one receptor
from a merged network (further discussion on this issue can be
found in Text S1).
In contrast to model construction from interaction databases or
large-scale association screens, our TCR and IL-2 networks
include only causal interactions that have been shown under
comparable experimental conditions. This explains the rather
sparse network structure, compared to say interactome database
models, but sparseness is not a necessary prerequisite for applying
the merging process. We believe that such a well-curated model is,
applying Occam’s Razor, often more helpful in understanding
cellular behavior than a model that includes all potential
interactions. Clearly, the scalability of the merging process
depends on two factors: The first is our ability to compute
intersections, unions, and induced subgraphs in labeled directed
graphs, which is computationally easy. The second is our ability to
solve SAT problems of a size less than or equal to a direct sum of
the parent networks. SAT problems are in a mathematical sense
computationally hard. There are however good implementations
of exact SAT solvers available that routinely handle problems with
200,000 variables and a million clauses. This appears to be
sufficient even for human interactome size networks. For the
merging process, the graph density or connectivity index of the
networks is not as much of importance as the structure of the
overlap. As noted, the complexity of computing a logical
projection is higher than that of solving an instance of SAT (see
Text S1), and in practice the difficulty here depends very much on
the amount of non-identical subnetworks that share many
components. Manual merging, however, has to perform the same
checks, which is always error-prone and quickly becomes
impossible even in models of the size of the TCR and IL-2
network presented here. Therefore, any automatic support is
useful in the model merging process, since it will always be faster
than solving the consistency checks by hand.
In the course of modeling, the question of how to consistently
merge two or more models arises in two contexts: First, when two
independently developed networks with some common compo-
nents shall be integrated into one network. And second, when
multiple extensions to a base model are to be merged, for example
after different parts of the base network have been refined. In the
merging algorithm (see Text S2) we call the existing networks
‘parents’, and the merged network ‘child’, hinting at the close
relationship with version control of data. The task of merging
cannot be completely automatized, unless one is satisfied with
annotating each statement with a label stating which network it
came from. In this case no overlap actually occurs, but the
resulting network is nothing more than a disjoint union of its
parents. Assuming compatible data quality many steps can be
automated and expert intervention is needed only in those cases
where it will lead to decisions about new experiments. We
implemented this in our in-house modeling system with about 300
lines of LISP code.
An attractive feature of the merging process of logical networks
is the ability to confirm the validity of cross-talk between pathways.
Not all possible cross-talks arising from the merging process are
feasible, since the activation patterns of each individual pathway
must be recovered in the combined network. In a typical situation,
a potential realization is that a cross-talk activates or inactivates
molecules that contradict the known activation pattern. Moreover,
the logical model is not only able to tell that a cross-talk contradicts
existing data; it can also offer minimal interventions to correct this
inconsistency [6]. In this way, the number of possible cross-talks is
reduced and/or modeling errors, which occurred during the initial
modeling or following the merging process, can be revealed. In
particular it allows us to determine late implication formulas that
usually describe negative feedback loops [3] (see Methods). Among
the set of identified pools of molecules that mediate cross-talk, the
logical model allows us to easily identify potential cross-inhibitions
among the pathways by commonly used negative regulators.
These may be either new potential cross-talks or can be ruled out
by existing data such that they must not be active during initiation
of signaling and are therefore molecules that are regulated by late
implication formulas. The identification of cross-inhibition is of
particular interest when applying sequential stimuli. The model
allows us to predict whether the pre-stimulation of one receptor
prevents the activation of particular pathways triggered by the
second receptor and finally the global outcome of sequential
stimulation.
Possible cross-talk between the TCR and IL-2R
We merged the validated IL-2R-network with our existing
TCR-model (Figure 5 and Figure S5 to yield Figure S6). The
merged network containing 150 components and 167 clauses (see
Table S2). The merging process generated two classes of questions.
First, do commonly used signaling proteins form separate pools? If
not, is there cross-talk between pathways mediated by these
proteins? Second, provided signaling elements are commonly
triggered, can missing details for upstream activators in one
pathway be elucidated from the other signaling pathway? This
second question is similar to asking at which points two signaling
pathways feed into a shared signaling module. It also corresponds
to the transfer of information from one parent to the other, via the
child. By projecting a subnetwork we thus improve the details of
classical top-down receptor pathways. In summary, we ended up
with the following list of questions that encouraged experimental
consideration:
1. cAMP is an inhibitor of PI3K activation in the IL-2R signaling network.
cAMP is a known inhibitor of Lck and Fyn and this mechanism
has recently been shown to work for TCR signaling as well in
the context of cross-talk with the m-opioid receptor [37–39].
Since we already demonstrated a SFK-dependency of PI3K
activation (Figure 3B) we therefore did not consider it necessary
to investigate this question further.
2. One possible element for cross-talk can be PI3K. For example the
strong PI3K-dependence of ERK activation in both signaling
systems may give rise to cross-regulation between TCR and IL-
2R signaling mediated by PI3K.
3. The TCR and the IL-2R use different pathways to generate the second
messenger DAG (PLCc1 and PLD, respectively). However, it has
been suggested that the different DAG species trigger different
sets of effectors [40]. Still, it seems that DAG in both cases
activates PKCs [16,17,20–22,24,41] although the downstream
signaling component that may explain the pro-proliferative
Figure 5. Revised model of IL-2R signaling. The interpretation is similar to Figure 1. The revised connections after the IL-2 experiments in human
T blasts are taken into account as indicated in Figs. 2–4 with new connections (including validated potential interactions) shown as thick black lines
and removed connections as thick grey lines. The changes are also listed in Table S3. Note, that some connections based on below-quality-standard
data remain that are not highlighted (Table S2).
doi:10.1371/journal.pcbi.1002121.g005
TCR and IL-2R Cross-Talk
PLoS Computational Biology | www.ploscompbiol.org 9 August 2011 | Volume 7 | Issue 8 | e1002121TCR and IL-2R Cross-Talk
PLoS Computational Biology | www.ploscompbiol.org 10 August 2011 | Volume 7 | Issue 8 | e1002121effect of PKC activation in IL-2R signaling had not been
identified previously [16,17,20–23]. We could show that,
similar to TCR signaling, ERK activation depends on novel
PKCs (Figure 4B) suggesting that the origin of DAG is
irrelevant for PKC activation and its effects on ERK. In
addition, DAG effectors may be commonly used by the IL-2R
and the TCR. The RAS activator RasGRP1 is such an effector
that is present in the TCR signaling network, but has been
excluded from IL-2R signaling by a recent study [42].
4. In the IL-2R signaling network the activation of SHP2 by recruitment to
the adaptor GAB2 can be prevented by ERK. Engaging this question
experimentally in primary cells has proved challenging due to a
lack of suitable reagents directed against GAB2. Thus, it
remains an open question whether ERK can modulate SHP2-
GAB2 interactions in TCR signaling.
5. Both receptors activate the SFKs Lck and Fyn. However, it is not clear
whether common pools are used or if cross-activation is
possible. Although we have excluded a role for SFKs in the
activation of STAT3 and STAT5 by the IL-2R, the possibility
that SFKs mediate STAT activation under other conditions
still exists [43].
6. The pathways leading to p38 and JNK activation are known in quite some
detail for the TCR network, but not for IL-2R signaling. This suggests
that we experimentally verify whether some, all, or none of
these elements are utilized by the IL-2R.
STAT activation upon TCR stimulation
One report demonstrated that Lck is able to phosphorylate
STAT proteins in vitro and although being activated after IL-2
stimulation, Lck is not required for IL-2R-mediated STAT
activation (see Figure 3B) [13]. Since SFKs can activate STATs
under other circumstances [43], we thought to test in the context
of TCR signaling whether the phosphorylation of STATs by Lck
and/or Fyn may play a role. We therefore looked for the
activation of STAT3 and STAT5 after TCR stimulation using
cross-linked CD36CD28 in both primary human T cells and
human T-cell blasts. Following TCR-stimulation, both phospho-
STAT3 and phospho-STAT5 are weakly induced in naı ¨ve T cells,
but not in T-cell blasts (Figure 7). A basal level of STAT tyrosine
phosphorylation is present in naı ¨ve T-cells, but absent in T-cell
blasts in the case of STAT5. Moreover it appears that STAT3
tyrosine phosphorylation is lost upon TCR stimulation in human
T-cell blasts (Figure 7). Since STATs are downstream of many
cytokine receptors involved in homeostatic signaling of T cells, the
suppression of STAT3 activation by the TCR may represent a
mechanism to switch off certain homeostatic signals upon TCR
stimulation. In summary, TCR and IL-2R may cross-talk via a
common pool of SFKs; however this question will require further
investigation. An alternative possibility could be that STATs are
activated by a member of the Syk family of protein tyrosine kinases
[13]. The TCR is reported to activate both ZAP-70 and Syk [45],
although substrates for Syk in TCR signaling are not well defined.
A third option is that TCR activates JAKs directly, however this
possibility has been excluded by a previous study [44].
The phosphorylation of both STAT3 and STAT5 following
TCR stimulation has previously been reported in T-cell lines
[45,46]. Both studies also demonstrated that STAT activation was
dependent on SFKs. In addition, another study demonstrated that
JAKs are not induced by TCR stimulation [44]. These studies
were not included in our TCR signaling network for two reasons:
First, each was reported only once and second, there exist
conflicting reports claiming the absence of STAT3 or STAT5
activation upon TCR stimulation in human T cells [44,46].
Interestingly, our logical modeling approach suggested that the
TCR mediates STAT activation, thus we were able to resolve
these conflicting reports for the human system and demonstrated
for the first time STAT3 activation following TCR stimulation in
naı ¨ve human T cells. Of the conflicting reports, the study using a
human CD4
+ T-cell line [46] is in agreement with our results for
naı ¨ve T cells that STAT3 can be activated after TCR stimulation
and suggests that the cell line is more naı ¨ve T-cell like. Also the
inability of TCR stimulation to induce STAT3 activity in human
T-cell blasts [44] is in agreement with our results for human T-cell
blasts and highlights a difference in TCR signaling in naı ¨ve human
T cells versus human T-cell blasts. In agreement with our results in
Figure 6. Questions arising during the model merging process. To merge networks, the components of the system require standardization,
i.e. components with identical names refer to the same molecule, and the interpretation of their activity states must be consistent. For this example,
components colored in green or blue represent the TCR or IL-2R pathways, respectively. During the merging process, the following types of questions
appear. In these examples, components highlighted in red represent the focus of a particular question. Grey lines represent potential interactions.A )
Implication formulas for the activation of one node have overlapping, but non-identical left-hand-sides, e.g. GAB2RSHP2 versus NOT ERK AND
GAB2RSHP2. These clauses differ with respect to ERK. The question is whether ERK always inhibits SHP2 or whether this is a network-specific event
involving (unknown) additional regulators that ensure receptor-specificity. B) Two implication formulas for the activation of a node have no overlap.
In the simplest case, the mediators are receptor-specific and there is no conflict. If downstream components are activated by one receptor does this
mean that these same components are also activated by the other? C) Two implication formulas for the activation of a node have no overlap. It is
possible that one is only a simplification of the other that omits intermediate steps. In the IL-2R network JNK is activated directly by SFKs. While the
TCR network contains multiple pathways leading to JNK. The first statement is not wrong, since all of these pathways are themselves SFK-dependent.
However, the information available is not precise enough to distinguish which pathway is involved. D) The implications formulas depend on different
isoforms, e.g. novel PKCs (nPKCs) versus PKCh which is one member of the nPKCs. Hence, whenever one isoform (PKCh) is activated, every interaction
involving the more general class of proteins (nPKCs) may also be affected and vice versa.
doi:10.1371/journal.pcbi.1002121.g006
Figure 7. Cross-talk of the TCR and IL-2R signaling network. (A)
STAT activation after TCR-stimulation. (B) Naı ¨ve T cells were stimulated
with cross-linked CD36CD28 for the indicated time. T-cell blasts were
stimulated with IL-2 or re-stimulated with cross-linked CD36CD28 for
the indicated times. The tyrosine phosphorylation of STAT3 and STAT5
was analyzed by Western blotting. ERK activation was analyzed to
confirm proper stimulation of the TCR. b-actin was analyzed as loading
control.
doi:10.1371/journal.pcbi.1002121.g007
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after stimulation with cross-linked anti-CD3 or peptide-loaded
antigen-presenting cells [45] confirming that the STAT activation
takes place under physiologic stimulation conditions. We could
also confirm that STAT3 and STAT5 are activated following
TCR stimulation in naı ¨ve mouse T cells as well as in mouse T-cell
blasts (Figure S7). Taken together, the subtle differences in STAT3
and STAT5 activation point towards a rewiring of the signaling
networks in activated human T cells that appears to be species-
specific as these differences are not observed in mice. A potential
role for CIS in mediating the block in TCR-induced STAT
activation in T-cell blasts can be excluded, as IL-2R-mediated
STAT activation is normal [47]. TCR-mediated STAT activation
should support proliferation and cell survival as STATs are known
to activate a number of important genes including cyclins as well
as members of the Bcl-family [48].
LAT is phosphorylated following IL-2R stimulation
The merging of signaling networks also allows a well-defined
information transfer between receptor pathways. The level of
detail with respect to the activation of certain pathways is usually
different for two receptors. In our networks, this applies in
particular to the activation of JNK after IL-2 stimulation.
However, merging with the TCR signaling network provided
essentially two pathways: Rac/Cdc42 activation or a pathway via
HPK1 (Figure 8A). As it is notoriously difficult to show HPK1
activation in primary cells, we looked to see whether LAT is
involved in IL-2 mediated JNK activation, as in TCR signaling
HPK1 is known to influence JNK activation via the LAT complex
[49,50]. Indeed LAT becomes tyrosine phosphorylated following
IL-2 stimulation of human T-cell blasts (Figure 8B). Thus, we have
uncovered a known pathway that was previously not described to
be involved in IL-2R signaling. Elucidation of this connection will
require further investigation, as our TCR network predicts a
number of downstream effectors of LAT that may now also be
triggered by IL-2. Therefore, we propose that phosphorylation of
LAT may be a first indicator to the JNK-activation pathway in IL-
2 stimulated human T-cell blasts. An additional consequence is
that our model now predicts several completely new signaling
branches with respect to IL-2R signaling such as Vav and SLP-76
(SH2 domain containing leukocyte protein of 76 kDa), which may
be shared with the TCR and will require further experimental
investigation.
A recent study has also revealed a potential role for IL-2 in the
homeostatic proliferation of naı ¨ve CD8
+ T cells [49]. Although
our network was established for the high affinity receptor, the
signaling network should be largely valid as signaling occurs via
the cytoplasmic tail of the b- and common c-chain of the IL-2R
([5] and references in Table S2). Thus, our result that LAT is
involved in IL-2R signaling may also apply to naı ¨ve T cells. It also
correlates nicely with the observation by Cho et al. [51] that the
IL-2 response of naı ¨ve CD8
+ T cells depends on the recruitment of
the IL-2Rb-chain into lipid rafts were LAT is localized [52] and
our observation of IL-2-induced LAT phosphorylation may
constitute the molecular mechanism behind the observations of
Cho et al.
The final issue remaining is what influence IL-2 has upon TCR
signaling. One could envision that these signals might intersect
during clonal expansion. Potential points of intersection are at the
level of DAG, SHP1, Lck, and/or PI3K. The first two have the
potential for inhibition, whereas the latter may work synergisti-
cally. The Boolean nature of the model prevents a reliable
prediction of synergistic increase of the activation of a pathway
since the component is either ON or OFF and there exists no state
with higher activity than ON. We can however calculate the effect
of IL-2 pre-stimulation on subsequent TCR signaling. We opted
Figure 8. Potential pathways to JNK activation for IL-2R
signaling derived from TCR signaling. (A) The TCR signaling
network offers two main routes to JNK activation involving the key
molecules Rac/Cdc42 and HPK1. A number of upstream events known
for TCR signaling may also be triggered by IL-2R signaling. (B) T-cell
blasts were stimulated with IL-2 for the indicated times. STAT5 and LAT
phosphorylation were analyzed by Western blotting. STAT5 phosphor-
ylation indicates successful IL-2 stimulation. b-actin was analyzed as
loading control.
doi:10.1371/journal.pcbi.1002121.g008
Figure 9. Influence of IL-2 upon TCR signaling. Human T-cell
blasts were stimulated with either CD36CD28 alone, IL-2 alone, both
receptors stimulated simultaneously, or the cells pretreated with IL-2 for
30 min before adding CD36CD28. Following application of the stimuli,
samples were taken for analysis at the times indicated. Blots were
probed with the antibodies indicated.
doi:10.1371/journal.pcbi.1002121.g009
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down-regulate TCR expression following activation. Additionally,
we know from our previous work [53] that autocrine IL-2 does not
prevent sustained TCR signaling. Taking into account that with
IL-2 prestimulation the TCR stimulation occurs when IL-2R
signaling is already in its late phase, the Boolean network predicts
that ERK and AKT remain inactive after stimulation of the TCR
(Table S3). To address this question experimentally we stimulated
human T-cell blasts with either CD36CD28 alone, IL-2 alone,
both receptors simultaneously, or pre-treated the cells for 30 min
with IL-2 before adding CD36CD28 (Figure 9). As a control, the
level of receptor surface expression was monitored to ensure that
IL-2 pre-treatment did not alter the level of surface TCR (see
Figure S8). From the data presented, it appears that costimulation
of both receptor systems has an additive effect, potentially via Lck
and/or PI3K. However, due to the discretization of the model,
such effects are not represented. Here, molecules are simple active
or not and changes in the level of activity are therefore not
described. In contrast, pre-incubation with IL-2 appears to result
in a desensitization of the cells towards TCR stimulation
suggesting activation of negative regulators, such as SHP1. The
inhibitory effect is most striking for ERK, AKT, and LAT, which
are predominately utilized by the TCR. We therefore concluded
that the temporal application of stimuli is critical for interpreting
the consequence of cross-talk.
Following T-cell activation, the activated T-cell clone rapidly
expands into an effector population. As the number of T cells
outnumbers the APC one could envision that a period of
desensitization towards further TCR signaling might benefit the
immune response by preventing the TCR-induced stop signal
[54]. Thus allowing activated T cells to escape the lymph node
and migrate into the periphery.
Conclusion
In summary, our results demonstrate the importance of
investigating receptor cross-talk and show that logical modeling
is indeed an appropriate method to address this topic. The TCR
and the IL-2R are two receptors for which the signaling events are
known in great detail. However, our investigation of the merged
receptor networks has allowed us to uncover previously unknown
events in both signaling pathways as well as to identify points of
intersection. An improved understanding of the molecular
interactions is important as targeting molecules for therapeutic
intervention in one pathway may influence the function of
another. Our merged model allows us to predict these apparent
‘‘off-target’’ effects and should permit the design of proper
alternative strategies that selectively modulates only the desired
pathway. As these signaling pathways are important for T-cell
differentiation, our ability to modulate them may enable cellular
reprogramming to shift the balance towards a regulatory
phenotype for treating autoimmune disease or towards an
activated phenotype for enhancing anti-tumor responses.
The recent study by Naldi et al. applies a logical framework to
analyze T-cell differentiation [55]. Given the complexity of the
system, the authors utilize a model reduction approach to explore
T-cell differentiation in silico. Since differentiation results from the
input of multiple signaling pathways, there is also a great potential
for cross-talk. Therefore, it would be interesting to combine
individual signaling networks with the differentiation model to see
if the combined approach provides a better insight into T-cell
differentiation. This would be particularly relevant for predicting
the influence of TCR-induced STAT activation upon the signaling
networks of the various cytokine receptors. One task would be the
conversion of logical models into dynamic ones, which can be
performed using the tool developed by [56]. However, one
challenge will be to constrain the parameters. In this case, studies
on the effects of IL-2 on T-cell proliferation, survival, and
population dynamics should be taken into account [8–10,57,58].
We believe that only by utilizing multiple models with varying
levels of complexity can we hope to improve our understanding of
T cell biology.
Supporting Information
Figure S1 A feasible negative feedback loop. Usually the
cycle of FYN, PAG, CSK, and LCKP1 would lead to an infeasible
solution as the activating interactions (solid lines) between the four
proteins demand that they are in the same state. This is in conflict
with the inhibition of LCKP1 by CSK (dotted red line) which
requires that one of them is active and the other inactive. As a
consequence one or more of the interactions needs to be classified
as a late implication formula. However, the additional input by
TCRB allows a feasible solution by creating flexibility in the state
of PAG.
(TIF)
Figure S2 Determination of CD25 and Annexin V/PI by
FACS staining. After resting for 24 hr and before restimulation
with IL-2, T-cell blasts were stained with a FITC-coupled anti-
CD25 antibody to determine the percentage of CD25-positive
cells (A) or a FITC-coupled Annexin V antibody and propidium
iodide to determine the number of viable cells (B).
(TIF)
Figure S3 Dose response of IL-2. Human T-cell blasts were
stimulated by the indicated dilutions of IL-2 [10,000 U]. Cell
lysates were analyzed by Western blotting for phosphorylated
ERK and STAT3. b-actin was analyzed as loading control.
(TIF)
Figure S4 The reversible SFK inhibitor PP2 does not
fully block AKT. The blot is a longer exposure of the blots of
Figure 3B and 4B demonstrating that the irreversible PI3K
inhibitor WM is more efficient than PP2 in blocking SFK-
dependent AKT-phosphorylation following IL-2 stimulation.
(TIF)
Figure S5 The TCR/CD4/CD28 signaling network. To a
large extent the signaling network was published previously in a
different graphical layout [3]. The top layer represents input
nodes. The bottom layer represents the output, i.e. molecules
including transcription factors that become activated. Solid black
arrows indicate activating interactions with a black circle denoting
AND-connections. For clarity, activating influences with arrows
pointing from the bottom to the top are drawn with dashed black
lines. Red lines mark inhibitory influences that are expressed as
NOT-conditions in the logical network. Note that some connec-
tions are based on below-quality-standard data (‘‘potential
connections’’), but are not highlighted separately (Table S2).
Detailed descriptions for the interpretation of each node can be
found in Table S1.
(TIF)
Figure S6 The merged network of TCR/CD4/CD28 and
IL-2R signaling. The top layer represents input nodes. The
bottom layer represents the output, i.e. molecules including
transcription factors that become activated. Solid black arrows
indicate activating interactions with a black circle denoting AND-
connections. For clarity, activating influences with arrows pointing
from the bottom to the top are drawn with dashed black lines.
Red lines mark inhibitory influences that are expressed as
TCR and IL-2R Cross-Talk
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are based on below-quality-standard data (‘‘potential connections’’),
but are not highlighted separately (Table S2). The nodes specific to
the IL-2R and TCR network are shown in blue and green,
respectively. Common nodes are highlighted in red; those marked
with a thick line are potential mediators of negative cross-regulation
identified by the merging process. Newly identified common
signaling elements retain their original color, i.e. blue green nodes
respectively, but are now marked with a thick line. The new
interactions investigated in the study are indicated by bold arrows. A
detailed description of each node can be found in Table S1.
(TIF)
Figure S7 STAT activation after TCR stimulation of
mouse T cells. Primary mouse T cells and mouse T-cell blasts
were stimulated as indicated in Protocol S1 and analyzed by
Western blotting for the activation of STAT3 and STAT5.
Irrelevant lanes have been cut out from the blots.
(TIF)
Figure S8 IL-2R signaling does not affect TCR expres-
sion. Human T-cell blasts were either stimulated with IL-2 for
30 min or left untreated. The level of TCR (CD3) and IL-2Ra
(CD25) surface expression were measured by flow cytometry.
Unstained cells are indicated with the broken line, untreated cells
are represented with the grey line, and stimulated cells indicated
by the black line.
(TIF)
Protocol S1 Stimulation of mouse T cells. Method
describing the isolation, culture, and stimulation of primary mouse
T cells and mouse T-cell blasts.
(PDF)
Text S1 Model merging as an IFFSAT problem. Restating
the problem of merging two networks as a projection of a larger
network, including a formal proof of the algorithmic complexity.
(PDF)
Text S2 Protocol for Boolean model merging. A step-by-
step protocol for the semi-automated merging of Boolean
networks.
(PDF)
Table S1 List of network components. The components of
the merged TCR-IL-2R network including biological names and
interpretation of the ON state.
(PDF)
Table S2 List of clauses for the merged network. The
implication formulas for each component of the merged network
are provided along with references supporting the interactions.
(PDF)
Table S3 Activation states of the merged network upon
different stimuli. Lists the state vectors for the merged network
with TCR and IL-2R stimulation alone or in combination.
(PDF)
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